| Database ID | Agent | Target | Cancer Type | Detail |
| DB00256 | cetuximab | Epidermal growth factor receptor | head and neck cancer | view |
| DB00257 | cetuximab | Epidermal growth factor receptor | head and neck cancer | view |
| DB00258 | cetuximab and lapatinib | NA | advanced solid tumors | view |
| DB00259 | cetuximab | Epidermal growth factor receptor | head and neck cancer | view |
| DB00260 | cetuximab | Epidermal growth factor receptor | head and neck cancer | view |
| DB00261 | cetuximab | Epidermal growth factor receptor | head and neck cancer | view |
| DB00262 | afatinib | Receptor proteintyrosine kinase erbB2
Epidermal growth factor receptor | head and neck cancer | view |
| DB00263 | cetuximab | Epidermal growth factor receptor | head and neck cancer | view |
| DB00264 | cetuximab | Epidermal growth factor receptor | head and neck cancer | view |
| DB00265 | cetuximab | Epidermal growth factor receptor | head and neck cancer | view |
| DB00266 | everolimus | Serine/threonineprotein kinase mTOR | head and neck cancer | view |
| DB00267 | cetuximab | Epidermal growth factor receptor | non small cell lung cancer | view |
| DB00268 | cetuximab | Epidermal growth factor receptor | head and neck cancer | view |
| DB00269 | cetuximab | Epidermal growth factor receptor | head and neck cancer | view |
| DB00270 | afatinib | Receptor proteintyrosine kinase erbB2
Epidermal growth factor receptor | head and neck cancer | view |